# Carlsmed, Inc.: overview CARL · Nasdaq · CIK 1794546 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/carl.md) · [Financials](/companies/carl/financials.md) · [Filings](/companies/carl/filings.md) · [Insiders](/companies/carl/insiders.md) Latest reported revenue: [$18.9m](/filings/0001794546-26-000016.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001794546-26-000016). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.6](/filings/0001193125-25-269545.md) | [9.4 d](/filings/0001193125-26-071551.md) | [10.2](/filings/0001794546-26-000011.md) | [12.1](/filings/0001794546-26-000016.md) | [13.1](/filings/0001193125-25-269545.md) | [15.2 d](/filings/0001193125-26-071551.md) | [16.1](/filings/0001794546-26-000011.md) | [18.9](/filings/0001794546-26-000016.md) | | Gross margin | % | [72.8%](/filings/0001193125-25-269545.md) | [74.7% d](/filings/0001193125-26-071551.md) | [74.9%](/filings/0001794546-26-000011.md) | [73.4%](/filings/0001794546-26-000016.md) | [75.9%](/filings/0001193125-25-269545.md) | [76.5% d](/filings/0001193125-26-071551.md) | [77.1%](/filings/0001794546-26-000011.md) | [76.8%](/filings/0001794546-26-000016.md) | | Operating margin | % | [(118.0%)](/filings/0001193125-25-269545.md) | [(49.9%) d](/filings/0001193125-26-071551.md) | [(56.1%)](/filings/0001794546-26-000011.md) | [(53.8%)](/filings/0001794546-26-000016.md) | [(69.1%)](/filings/0001193125-25-269545.md) | [(61.4%) d](/filings/0001193125-26-071551.md) | [(57.6%)](/filings/0001794546-26-000011.md) | [(58.3%)](/filings/0001794546-26-000016.md) | | Net margin | % | [(118.6%)](/filings/0001193125-25-269545.md) | [(50.2%) d](/filings/0001193125-26-071551.md) | [(56.2%)](/filings/0001794546-26-000016.md) | [(56.0%)](/filings/0001794546-26-000016.md) | [(65.2%)](/filings/0001193125-25-269545.md) | [(56.8%) d](/filings/0001193125-26-071551.md) | [(54.0%)](/filings/0001794546-26-000016.md) | [(55.5%)](/filings/0001794546-26-000016.md) | | Diluted EPS | $ per share | [(2.06)](/filings/0001193125-25-269545.md) | not reported | [(1.47)](/filings/0001794546-26-000011.md) | [(1.47)](/filings/0001794546-26-000016.md) | [(0.40)](/filings/0001193125-25-269545.md) | not reported | [(0.32)](/filings/0001794546-26-000011.md) | [(0.39)](/filings/0001794546-26-000016.md) | | Free cash flow | $m | [(7.6) d](/filings/0001193125-25-269545.md) | [(4.3) d](/filings/0001193125-26-071551.md) | [(8.2)](/filings/0001794546-26-000011.md) | [(7.4) d](/filings/0001794546-26-000016.md) | [(8.6) d](/filings/0001193125-25-269545.md) | [(5.4) d](/filings/0001193125-26-071551.md) | [(13.1)](/filings/0001794546-26-000011.md) | [(7.5) d](/filings/0001794546-26-000016.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | [27.2](/filings/0001193125-26-071551.md) | [50.5](/filings/0001193125-26-071551.md) | | Gross margin | % | [73.8%](/filings/0001193125-26-071551.md) | [75.3%](/filings/0001193125-26-071551.md) | | Operating margin | % | [(88.8%)](/filings/0001193125-26-071551.md) | [(60.5%)](/filings/0001193125-26-071551.md) | | Net margin | % | [(89.3%)](/filings/0001193125-26-071551.md) | [(58.7%)](/filings/0001193125-26-071551.md) | | Diluted EPS | $ per share | [(6.11)](/filings/0001193125-26-071551.md) | [(2.12)](/filings/0001193125-26-071551.md) | | Free cash flow | $m | [(25.6)](/filings/0001193125-26-071551.md) | [(29.6)](/filings/0001193125-26-071551.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/carl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $13.0m | 1,251,616 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $11.1m | 1,227,452 | | Not compared | | [Parkman Healthcare Partners LLC](/funds/1777015.md) | 2026-06-30 | $6.2m | 597,318 | | Added +76,195 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.5m | 532,593 | | Added +85,701 | | [KCM Capital Inc](/funds/2026745.md) | 2026-06-30 | $4.6m | 440,000 | | Added +240,000 | | [Pier Capital, LLC](/funds/1310051.md) | 2026-06-30 | $3.9m | 373,677 | | New +373,677 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $3.1m | 295,907 | | New +295,907 | | [Palumbo Wealth Management LLC](/funds/1846310.md) | 2026-06-30 | $2.8m | 267,298 | | New +267,298 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.5m | 238,727 | | Reduced −37,404 | | [Schonfeld Strategic Advisors LLC](/funds/1665241.md) | 2026-06-30 | $2.3m | 224,804 | | Reduced −58,376 | ## Recent filings [All 93 filings](/companies/carl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 09:15 ET | [8-K](/filings/0001794546-26-000020.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001794546-26-000020 | | 2026-09-08 | 16:06 ET | [8-K](/filings/0001794546-26-000018.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001794546-26-000018 | | 2026-08-05 | 16:10 ET | [10-Q](/filings/0001794546-26-000016.md) | Quarterly report, period 2026-06-30 | 0001794546-26-000016 | | 2026-08-05 | 16:05 ET | [8-K](/filings/0001794546-26-000015.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001794546-26-000015 | | 2026-06-03 | 16:05 ET | [8-K](/filings/0001193125-26-255404.md) | 5.07 Shareholder vote results | 0001193125-26-255404 | | 2026-05-05 | 16:10 ET | [10-Q](/filings/0001794546-26-000011.md) | Quarterly report, period 2026-03-31 | 0001794546-26-000011 | | 2026-05-05 | 16:05 ET | [8-K](/filings/0001794546-26-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001794546-26-000010 | | 2026-04-22 | 08:30 ET | [DEF 14A](/filings/0001794546-26-000005.md) | Proxy statement, period 2026-06-03 | 0001794546-26-000005 | | 2026-02-25 | 16:09 ET | [10-K](/filings/0001193125-26-071551.md) | Annual report, period 2025-12-31 | 0001193125-26-071551 | | 2026-02-25 | 16:05 ET | [8-K](/filings/0001193125-26-071512.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071512 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-071551.md), filed Feb 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0a9575de-6305-4716-a58e-82ecb68395ea) ## About the filer - CIK: 1794546 - Tickers: CARL - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 09:38 ET. No prices; not investment advice.